TITLE

Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke

AUTHOR(S)
ZOPPO, GREGORY J. DEL; VON KUMMER, RÜDIGER; HAMANN, GERHARD F
PUB. DATE
July 1998
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jul1998, Vol. 65 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66329533

 

Related Articles

  • Novel Thrombolytic Drugs: Will They Make a Difference in the Treatment of Ischaemic Stroke? Meretoja, Atte; Tatlisumak, Turgut // CNS Drugs;2008, Vol. 22 Issue 8, p619 

    Treatment of acute ischaemic stroke aims to recanalize the occluded artery, salvage the at-risk brain tissue and thus minimize neurological sequelae. Efforts a decade ago have led to the only currently approved medical treatment for acute ischaemic stroke, i.e. intravenous alteplase given within...

  • Intracerebral haemorrhage revisited.  // QJM: An International Journal of Medicine;Oct2007, Vol. 100 Issue 11, p715 

    Much evidence suggests that acute intracerebral haemorrhage usually starts to appear an hour or two after a thromboembolic brain infarct. Intravenous thrombolytic treatment is accepted treatment for acute ischaemic stroke; but all neurologists concur that brain imaging should be performed first,...

  • Collateral damage in acute stroke treatment: a new role for an old concept? Warburton, Liz // Journal of Neurology, Neurosurgery & Psychiatry;Jun2008, Vol. 79 Issue 6, p615 

    The article presents views and insights of the author concerning the collateral damage in acute ischaemic stroke treatment. According to the author, the major determinant of clinical recovery in acute ischaemic stroke is early reperfusion of the ischaemic penumbra. Major advances in brain...

  • Thrombolytics in Acute Ischaemic Stroke: A Guide to Patient Selection and Optimum Use. Adams, H.P. // BioDrugs;2000, Vol. 13 Issue 2, p115 

    Intravenously administered alteplase (recombinant tissue plasminogen activator; rtPA) is the only medical treatment that has been approved for the management of acute ischaemic stroke. Although rtPA has demonstrated efficacy in improving outcomes of patients with a wide range of neurological...

  • Easing the effects of a stroke. Blue, Felicia R. // Crain's Cleveland Business;12/18/95, Vol. 16 Issue 51, p17 

    Reports on a study at University Hospitals of Cleveland, Ohio regarding the treatment of stroke patients with the thrombolytic agent urokinase. Role of the drug in minimizing the damage done by strokes; Reduction in the cost of treating stroke patients; Injection of the drug into blood vessels...

  • Intravenous thrombolysis in acute ischaemic stroke: optimising its use in routine clinical practice. Bravata, Dawn M. // CNS Drugs;2005, Vol. 19 Issue 4, p295 

    Stroke is a common and important medical problem. Intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; rtPA) is the only available direct treatment that reduces neurological injury following ischaemic stroke. Strong efficacy data from randomised, controlled trials...

  • Therapeutic Potential of Ancrod in the Management of Cerebrovascular Disorders. Benavente, O.; Sherman, D.G. // CNS Drugs;1998, Vol. 9 Issue 5, p341 

    Ischaemic stroke is a major public health problem. Thrombus formation and occlusion of an artery are of paramount importance in the aetiology of focal cerebral ischaemia. Thrombosis is an active process, involving endothelium, coagulation system activation, platelet aggregation and thrombus...

  • Antibody cuts brain damage in strokes. Geddes, Linda // New Scientist;7/10/2010, Vol. 207 Issue 2768, p01 

    The article discusses a drug treatment using an antibody that helps prevent damage caused by stroke, such as reduced blood flow to the brain. Topics include an overview of the preferred treatment for ischaemic stroke, which is the drug rtPA, the risks and benefits of administering rtPA, and the...

  • Thrombolytic Agents for Acute Ischaemic Stroke Treatment: The Past, Present and Future. Balami, Joyce S.; Ruoli Chen; Sutherland, Brad A.; Buchan, Alastair M. // CNS & Neurological Disorders - Drug Targets;Mar2013, Vol. 12 Issue 2, p145 

    Despite advances in the diagnosis and treatment of acute ischaemic stroke in the past two decades, stroke has remained the third cause of mortality and the single leading cause of disability worldwide. The immediate goal of acute ischaemic stroke therapy is to salvage the ischaemic penumbra...

  • Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials. Gumbinger, Christoph; Reuter, Björn; Stock, Christian; Sauer, Tamara; Wiethölter, Horst; Bruder, Ingo; Rode, Susanne; Kern, Rolf; Ringleb, Peter; Hennerici, Michael G.; Hacke, Werner // BMJ: British Medical Journal;6/7/2014, Vol. 348 Issue 7961, p12 

    STUDY QUESTION Does thrombolytic therapy for acute ischaemic stroke have a similar time dependent benefit/risk ratio in clinical practice to that seen in pooled analyses of randomised clinical trials? SUMMARY ANSWER In patients with acute ischaemic stroke treated with thrombolytic therapy in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics